Asia Pacific Plasmid Dna Manufacturing Market Size & Outlook
Related Markets
Asia Pacific plasmid dna manufacturing market highlights
- The Asia Pacific plasmid dna manufacturing market generated a revenue of USD 502.7 million in 2025.
- The market is expected to grow at a CAGR of 19.7% from 2026 to 2033.
- In terms of segment, gmp grade was the largest revenue generating grade in 2025.
- GMP Grade is the most lucrative grade segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 502.7 million |
| Market revenue in 2033 | USD 2,087.6 million |
| Growth rate | 19.7% (CAGR from 2026 to 2033) |
| Largest segment | Gmp grade |
| Fastest growing segment | GMP Grade |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | R&D Grade, GMP Grade |
| Key market players worldwide | Charles River Laboratories International Inc, Danaher Corp, Kaneka Corp, Eurofins Scientific SE, Lonza Group Ltd, Akron Biotechnology, Luminous BioSciences, Lonza Group Ltd ADR, Cell & Gene Therapy, Nature Technology, VGXI |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 20.7% of the global plasmid dna manufacturing market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,087.6 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Plasmid DNA Manufacturing Market Scope
Plasmid DNA Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Nature Technology | View profile | 11-50 | Lincoln, Nebraska, United States, North America | https://www.natx.com |
| Cell & Gene Therapy | View profile | - | http://www.insights.bio/cell-and-gene-therapy-insights/ | |
| Luminous BioSciences | View profile | 251-500 | Gaithersburg, Maryland, United States, North America | https://www.luminousbio.com |
| VGXI | View profile | 101-250 | The Woodlands, Texas, United States, North America | https://vgxii.com/ |
| Lonza Group Ltd ADR | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| Akron Biotechnology | View profile | 11-50 | Boca Raton, Florida, United States, North America | https://www.akronbiotech.com |
| Kaneka Corp | View profile | 13284 | 3-2-4, Nakanoshima, Kita-ku, Osaka, Japan, 530-8288 | http://www.kaneka.co.jp |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Danaher Corp | View profile | 63000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | https://www.danaher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Asia Pacific plasmid dna manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Gmp grade was the largest segment with a revenue share of 102.31% in 2025. Horizon Databook has segmented the Asia Pacific plasmid dna manufacturing market based on r&d grade, gmp grade covering the revenue growth of each sub-segment from 2021 to 2033.
The Asia Pacific market for plasmid DNA manufacturing is expanding because of the growing incidence of target conditions and diseases, as well as the effectiveness of pDNA in delivering gene therapy. Furthermore, funding for the advancement of gene therapy as well as ongoing research on gene as well as cell therapies dependent on viral vectors are factors contributing to this growth.
A tremendous opportunity for the production of plasmid DNA was presented by the COVID-19 pandemic, thus propelling market growth. Increasing number of clinical trials with promising results, growing incidence of chronic diseases, and growing efforts to advance gene therapy are the main drivers of the market.
The clinical transformation and industrialization of gene therapy continue to steadily progress across Asian countries. For instance, in June 2021, Aldevron and Aruvant Sciences announced that Aldevron will contribute to developing ARU-1801, Aruvant's investigational gene therapies for Sickle Cell Disease (SCD), including ARU-2801, gene therapies for Hypophosphatasia (HPP).
Reasons to subscribe to Asia Pacific plasmid dna manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific plasmid dna manufacturing market databook
-
Our clientele includes a mix of plasmid dna manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific plasmid dna manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific plasmid dna manufacturing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific plasmid dna manufacturing market size, by country, 2021-2033 (US$M)
Asia Pacific Plasmid DNA Manufacturing Market Outlook Share, 2025 & 2033 (US$M)
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
